ONCOLYTICS BIOTECH INC
Developing an immuno-oncolytic virus to treat breast and gastrointestinal cancers.
ONCY | NDAQ
Overview
Corporate Details
- ISIN(s):
- CA6823108759
- LEI:
- Country:
- United States of America
- Address:
- 804, 322 - 11 AVENUE SW, CALGARY
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company developing pelareorep, an intravenously delivered immuno-oncolytic virus for cancer therapy. The company's lead product, pelareorep, is designed to selectively replicate within cancer cells, which in turn stimulates a patient's innate and adaptive immune systems to attack the tumor. This mechanism aims to enhance the efficacy of existing oncology treatments, including chemotherapy and immune checkpoint inhibitors. Oncolytics' clinical development is focused on indications such as HR+/HER2- breast cancer and various gastrointestinal cancers, including pancreatic cancer. The company collaborates with academic institutions and pharmaceutical partners to explore the broad potential of its therapeutic platform.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ONCOLYTICS BIOTECH INC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ONCOLYTICS BIOTECH INC
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ONCOLYTICS BIOTECH INC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
